BioAge reports Q3 2026 results, updates timelines for BGE-102 trials

BioAge Labs reported third-quarter 2026 financial results and pipeline updates on November 5, 2026.

The company said the first participant was dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema, in September 2026.¹ The study will enroll roughly 180 participants across three arms randomized 1:1:1, testing BGE-102 alone and combined with standard-of-care anti-VEGF therapy.¹ Its primary endpoint is change from baseline in best-corrected visual acuity at week 12, with topline results expected in the second half of 2027.¹

In the cardiovascular program, QUELL-CV, a randomized, double-blind, placebo-controlled dose-ranging study testing three once-daily doses of BGE-102 (30 mg, 60 mg and 90 mg) against placebo in adults with obesity and elevated baseline inflammation, finished enrolling about 160 participants.¹ Its primary endpoint is percent change from baseline in hsCRP over 12 weeks¹, with topline data expected in the fourth quarter of 2026.¹

On the obesity side, BioAge plans to submit its first IND for an APJ agonist program by the end of 2026.¹ The company also said its research collaborations with Novartis, Lilly ExploR&D, and Deep Origin continued to advance, with a Deep Origin-identified hit against a novel BioAge target validated in BioAge's lab in October 2026, now moving into hit-to-lead work.¹

Financially, net loss for the quarter was $33.5 million, or $0.73 per share, compared with a $20.2 million loss, or $0.56 per share, a year earlier.¹ As of September 30, 2026, BioAge held about $352.3 million in cash, cash equivalents and marketable securities, which it said should fund operations through 2029.¹